Catalent Continues Investment In Global Clinical SuppLy Services with GERMAN warehousing & controlled substance expansion

Catalent Pharma Solutions announced the completion of extended warehousing facilities in Schorndorf, Germany for its Clinical Supply Services business.

This increased capacity for the storage and distribution of Investigational Medicinal Products (IMPs) incorporates dedicated storage for controlled, highly potent or cytotoxic drugs.

The additional storage adds to Catalent's overall capability and the significant expansion brought about through the acquisition of Aptuit's Clinical Trial Supplies business completed earlier this year. Peter Brun, Director, Clinical Supply Services, notes that “The additional GMP storage capacity enhances Catalent's ability to support customers' global development and multi-centre clinical studies. Our Schorndorf facility's central European location is convenient to serve a wide area and assures customers of reliable supply throughout their development programs and on to commercial supply.”

This enhanced warehousing and controlled substance capability, combined with Catalent's offerings in comparator sourcing, clinical packaging and labeling, manufacturing and blinding, and distribution and warehousing allows Catalent to better meet the needs of virtually any size clinical trial, with any drug, anywhere in the world - a capability unmatched by competitors in the industry.
Companies in this article
More in Home